Drug
Neridronate
Neridronate: highest development phase Phase 3, developed by Ambros Therapeutics, Inc.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ambros Therapeutics, Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Neridronate NCT07210515 | Phase 3 | Complex Regional Pain Syndrome Type I |
Latest
No recent events.
Follow Neridronate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.